Defective acute inflammation in Crohn's disease: a clinical investigation
- PMID: 16503465
- DOI: 10.1016/S0140-6736(06)68265-2
Defective acute inflammation in Crohn's disease: a clinical investigation
Erratum in
- Lancet. 2007 Jul 28;370(9584):318
Abstract
Background: The cause of Crohn's disease has not been mechanistically proven. We tested the hypothesis that the disease is a form of immunodeficiency caused by impaired innate immunity.
Methods: We investigated inflammatory responses in patients and controls by quantifying neutrophil recruitment and cytokine production after acute trauma, interleukin 8 secretion by cultured monocyte-derived macrophages after exposure to inflammatory mediators, and local inflammatory and vascular changes in response to subcutaneous injection of heat-killed Escherichia coli.
Findings: In patients with Crohn's disease, trauma to rectum, ileum, or skin led to abnormally low neutrophil accumulation (differences from healthy individuals of 79%, n=8, p=0.0003; 57%, n=3, p=0.05; 50%, n=13, p<0.0001, respectively) and lower production of proinflammatory interleukin 8 (63%, n=7, p=0.003; 63%, n=3, p=0.05; 45%, n=8, p<0.0001) and interleukin 1beta (50%, n=8, p=0.0005). Interleukin 8 secretion by cultured macrophages was reduced after exposure to acute wound fluid (38%, n=50, p<0.0001), C5a (48%, n=41, p=0.0005), or tumour necrosis factor alpha (52%, n=27, p<0.0001). Local inflammatory reaction to inoculation with E coli was attenuated, as quantified by changes in bloodflow (ileal disease 50%, n=6, p=0.01; colonic disease 77%, n=6, p=0.0003). This response was mediated by nitric oxide in controls, was increased by sildenafil in patients, and was not related to CARD15 genotype.
Interpretation: In Crohn's disease, a constitutionally weak immune response predisposes to accumulation of intestinal contents that breach the mucosal barrier of the bowel wall, resulting in granuloma formation and chronic inflammation. Polymorphisms in CARD15 do not underlie this phenotype, but incapacitate the NOD2 pathway that can compensate for impairment of innate inflammation. Current treatment of secondary chronic inflammation might exaggerate the underlying lesion and promote chronic disease.
Comment in
-
Defective acute inflammation in Crohn's disease.Lancet. 2006 Aug 12;368(9535):577-8. doi: 10.1016/S0140-6736(06)69192-7. Lancet. 2006. PMID: 16905014 No abstract available.
-
Defective acute inflammation in Crohn's disease.Lancet. 2006 Aug 12;368(9535):578. doi: 10.1016/S0140-6736(06)69193-9. Lancet. 2006. PMID: 16905017 No abstract available.
-
Crohn's disease: the cost of comfortable inaction.Inflamm Bowel Dis. 2006 Dec;12(12):1185-6. doi: 10.1097/01.mib.0000246781.68130.29. Inflamm Bowel Dis. 2006. PMID: 17119393 No abstract available.
-
Impotent immune system: an underlying problem in Crohn's disease.Gastroenterology. 2007 Jun;132(7):2609-11. doi: 10.1053/j.gastro.2007.04.050. Gastroenterology. 2007. PMID: 17570236 No abstract available.
Similar articles
-
NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression.Gut. 2004 Nov;53(11):1658-64. doi: 10.1136/gut.2003.032805. Gut. 2004. PMID: 15479689 Free PMC article.
-
Reduced alpha-defensin expression is associated with inflammation and not NOD2 mutation status in ileal Crohn's disease.Gut. 2008 Jul;57(7):903-10. doi: 10.1136/gut.2007.142588. Epub 2008 Feb 27. Gut. 2008. PMID: 18305068
-
Cellular and molecular mechanisms underlying NOD2 risk-associated polymorphisms in Crohn's disease.Immunol Rev. 2014 Jul;260(1):249-60. doi: 10.1111/imr.12193. Immunol Rev. 2014. PMID: 24942694 Review.
-
Synergy between TLR9 and NOD2 innate immune responses is lost in genetic Crohn's disease.Gut. 2005 Nov;54(11):1553-7. doi: 10.1136/gut.2005.065888. Epub 2005 May 31. Gut. 2005. PMID: 15928043 Free PMC article.
-
Studies on patients establish Crohn's disease as a manifestation of impaired innate immunity.J Intern Med. 2019 Oct;286(4):373-388. doi: 10.1111/joim.12945. Epub 2019 Jun 27. J Intern Med. 2019. PMID: 31136040 Review.
Cited by
-
Site-Specific Immunomodulator: A Novel Treatment for Crohn's Disease.Gastroenterol Res Pract. 2015;2015:231243. doi: 10.1155/2015/231243. Epub 2015 May 12. Gastroenterol Res Pract. 2015. PMID: 26064087 Free PMC article.
-
Genetic insights into common pathways and complex relationships among immune-mediated diseases.Nat Rev Genet. 2013 Sep;14(9):661-73. doi: 10.1038/nrg3502. Epub 2013 Aug 6. Nat Rev Genet. 2013. PMID: 23917628 Review.
-
New treatment options in the management of IBD - focus on colony stimulating factors.Biologics. 2008 Sep;2(3):501-4. doi: 10.2147/btt.s3543. Biologics. 2008. PMID: 19707380 Free PMC article.
-
Pathway-based approaches to the treatment of inflammatory bowel disease.Transl Res. 2016 Jan;167(1):104-15. doi: 10.1016/j.trsl.2015.09.002. Epub 2015 Sep 7. Transl Res. 2016. PMID: 26408803 Free PMC article. Review.
-
Toll-like receptors regulate B cell cytokine production in patients with diabetes.Diabetologia. 2010 Jul;53(7):1461-71. doi: 10.1007/s00125-010-1730-z. Epub 2010 Apr 11. Diabetologia. 2010. PMID: 20383694 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical